Clinical research organisation is enjoying a strong and consistent period of growth in the United States marketplace, with more and larger projects, the majority being Phase III studies
Independent CRO Chiltern International celebrated a landmark this week with the announcement that its US operation had passed the 100-employee mark.
The company says it is enjoying a strong and consistent period of growth in the United States marketplace, not only handling more projects, but also much larger studies with the majority of work being Phase III studies.
The net revenues of the US operation have increased by 235% for the first nine months of 2004, compared to the same period in 2003.
Chiltern's first US office was opened in Atlanta, Georgia in 1999.
The second facility - in Austin, Texas - opened its doors for business in September 2000, and in March 2002, a third office was opened in Carlsbad, California.
The growth in business for the company in the United States has also been reflected in the number of new employees hired.
In December 2000, Chiltern had 35 US employees.
One year later, there were 58, and in December 2002, a total of 72 employees.
Today, there are 102 employees. "We have been fortunate to be able to hire employees with extensive US, and global experience," explained Aidan Nuttall, president of Chiltern.
"This experience, along with our proactive study management philosophy, has allowed Chiltern to demonstrate an alternative approach to clinical trials". "Chiltern's advantage is its ability to offer a global approach to clinical trials and yet retain the personal service that sponsors are looking for," added Diana Wood, vice president business development, USA.
"This has been key to building higher value, longer-lasting relationships with our clients and our achievements reflect this".
